Drink your prevention: Beverages with cancer preventive phytochemicals

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 12, 2014, Pages 713-722

  Rossi, Teresa ^a   Gallo, Cristina ^a   Bassani, Barbara ^b   Canali, Sara ^b   Albini, Adriana ^a   Bruno, Antonino ^b  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Beverages; Cancer prevention; Phytochemicals

Indexed keywords

CAFFEINE; EPIGALLOCATECHIN; OLIVE OIL; PLANT MEDICINAL PRODUCT; PROCYANIDIN; RESVERATROL; TRITERPENOID; XANTHOHUMOL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; TEA;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BEER; BEVERAGE; CACAO; CANCER PREVENTION; CHEMOPROPHYLAXIS; COFFEE; DIET SUPPLEMENTATION; FRUIT JUICE; HUMAN; NEOPLASM; NONHUMAN; RED WINE; REVIEW; TEA; CHEMISTRY; DIET THERAPY; FRUIT; NEOPLASMS; VEGETABLE;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BEVERAGES; FRUIT; HUMANS; NEOPLASMS; PHYTOCHEMICALS; TEA; VEGETABLES;

EID: 84920055144     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2560     Document Type: Review

References (100)

1. Winkels RM, Heine-Bröring RC, van Zutphen M, et al. The COLON study: Colorectal cancer: Longitudinal, Observational study on Nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer. 2014; 14: 374.
2. Dasgupta P, Baade PD, Aitken JF, Turrell G. Multilevel determinants of breast cancer survival: Association with geographic remoteness and arealevel socioeconomic disadvantage. Breast Cancer Res Treat. 2012; 132: 701-710.
3. Lian M, Schootman M, Doubeni CA, et al. Geographic variation in colorectal cancer survival and the role of small-area socioeconomic deprivation: A multilevel survival analysis of the NIH-AARP Diet and Health Study Cohort. Am J Epidemiol. 2011; 174: 828-838.
4. Baade PD, Turrell G, Aitken JF. A multilevel study of the determinants of area-level inequalities in colorectal cancer survival. BMC Cancer. 2010; 10: 24.
5. Sporn MB, Suh N. Chemoprevention: An essential approach to controlling cancer. Nat Rev Cancer. 2002; 2: 537-543.
6. Kelloff GJ, Boone CW, Crowell JA, et al. Chemopreventive drug development: Perspectives and progress. Cancer Epidemiol Biomarkers Prev. 1994; 3: 85-98.
7. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc. 1979; 38: 2528-2534.
8. Middleton E, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and cancer. Pharmacol Rev. 2000; 52: 673-751.
9. Schramm L. Going green: The role of the green tea component EGCG in chemoprevention. J Carcinog Mutagen. 2013; 4: 1000142.
10. Menard C, Bastianetto S, Quirion R. Neuroprotective effects of resveratrol and epigallocatechin gallate polyphenols are mediated by the activation of protein kinase C gamma. Front Cell Neurosci. 2013; 7: 281.
11. Fujiki H, Suganuma M, Imai K, Nakachi K. Green tea: Cancer preventive beverage and/or drug. Cancer Lett. 2002; 188: 9-13.
12. Du GJ, Zhang Z, Wen XD, et al. Epigallocatechin Gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients. 2012; 4: 1679-1691.
13. Fassina G, Vene R, Morini M, et al. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. Clin Cancer Res. 2004; 10: 4865-4873.
14. Leong H, Mathur PS, Greene GL. Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Res Treat. 2009; 117: 505-515.
15. Mineva ND, Paulson KE, Naber SP, et al. Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells. PLoS One. 2013; 8: E73464.
16. Masuda M, Suzui M, Lim JT, Weinstein IB. Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res. 2003; 9: 3486-3491.
17. Sah JF, Balasubramanian S, Eckert RL, Rorke EA. Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem. 2004; 279: 12755-12762.
18. Kumazoe M, Sugihara K, Tsukamoto S, et al. 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. J Clin Invest. 2013; 123: 787-799.
19. Sogno I, Vannini N, Lorusso G, et al. Anti-angiogenic activity of a novel class of chemopreventive compounds: Oleanic acid terpenoids. Recent Results Cancer Res. 2009; 181: 209-212.
20. Vannini N, Lorusso G, Cammarota R, et al. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Mol Cancer Ther. 2007; 6: 3139-3146.
21. Yore MM, Liby KT, Honda T, et al. The synthetic triterpenoid 1-2-cyano-3, 12-dioxooleana-1, 9(11)-dien-28-oylimidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther. 2006; 5: 3232-3239.
22. Ahmad R, Raina D, Meyer C, et al. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem. 2006; 281: 35764-35769.
23. Wang J, Liu L, Qiu H, et al. Ursolic acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells. PLoS One. 2013; 8: E63872.
24. Vene R, Larghero P, Arena G, et al. Glycogen synthase kinase 3beta regulates cell death induced by synthetic triterpenoids. Cancer Res. 2008; 68: 6987-6996.
25. Liby K, Voong N, Williams CR, et al. The synthetic triterpenoid CDDOImidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res. 2006; 12: 4288-4293.
26. Choi SH, Kim BG, Robinson J, et al. Synthetic triterpenoid induces 15-PGDH expression and suppresses inflammation-driven colon carcinogenesis. J Clin Invest. 2014; 124: 2472-2482.
27. Liu M, Reddy NM, Higbee EM, et al. The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice. Kidney international. 2014; 85: 134-141.
28. Kulkarni AA, Thatcher TH, Hsiao HM, et al. The triterpenoid CDDO-Me inhibits bleomycin-induced lung inflammation and fibrosis. PLoS One. 2013; 8: E63798.
29. Fki I, Bouaziz M, Sahnoun Z, Sayadi S. Hypocholesterolemic effects of phenolic-rich extracts of Chemlali olive cultivar in rats fed a cholesterol-rich diet. Bioorg Med Chem. 2005; 13: 5362-5370.
30. Park S, Choi Y, Um SJ, et al. Oleuropein attenuates hepatic steatosis induced by high-fat diet in mice. J Hepatol. 2011; 54: 984-993.
31. Giordano E, Dávalos A, Visioli F. Chronic hydroxytyrosol feeding modulates glutathione-mediated oxido-reduction pathways in adipose tissue: A nutrigenomic study. Nutr Metab Cardiovasc Dis. 2014; 24: 1144-1150.
32. Zhu L, Liu Z, Feng Z, et al. Hydroxytyrosol protects against oxidative damage by simultaneous activation of mitochondrial biogenesis and phase II detoxifying enzyme systems in retinal pigment epithelial cells. J Nutr Biochem. 2010; 21: 1089-1098.
33. Impellizzeri D, Esposito E, Mazzon E, et al. The effects of oleuropein aglycone, an olive oil compound, in a mouse model of carrageenan-induced pleurisy. Clin Nutr. 2011; 30: 533-540.
34. Fabiani R, De Bartolomeo A, Rosignoli P, et al. Cancer chemoprevention by hydroxytyrosol isolated from virgin olive oil through G1 cell cycle arrest and apoptosis. Eur J Cancer Prev. 2002; 11: 351-358.
35. Ragione FD, Cucciolla V, Borriello A, et al. Hydroxytyrosol, a natural molecule occurring in olive oil, induces cytochrome c-dependent apoptosis. Biochem Biophys Res Commun. 2000; 278: 733-739.
36. Aunon-Calles D, Canut L, Visioli F. Toxicological evaluation of pure hydroxytyrosol. Food Chem Toxicol. 2013; 55: 498-504.
37. Aunon-Calles D, Giordano E, Bohnenberger S, Visioli F. Hydroxytyrosol is not genotoxic in vitro. Pharmacol Res. 2013; 74: 87-93.
38. Servili M, Rizzello CG, Taticchi A, et al. Functional milk beverage fortified with phenolic compounds extracted from olive vegetation water, and fermented with functional lactic acid bacteria. Int J Food Microbiol. 2011; 147: 45-52.
39. Richard JL, Cambien F, Ducimetiere P. [Epidemiologic characteristics of coronary disease in France]. Nouv Presse Med. 1981; 10: 1111-1114. French.
40. Prasad K. Resveratrol, wine, and atherosclerosis. Int J Angiol. 2012; 21: 7-18.
41. Liu BL, Zhang X, Zhang W, Zhen HN. New enlightenment of French Paradox: Resveratrol's potential for cancer chemoprevention and anti-cancer therapy. Cancer Biol Ther. 2007; 6: 1833-1836.
42. Chen Q, Ganapathy S, Singh KP, et al. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One. 2010; 5: E15288.
43. Srivastava RK, Unterman TG, Shankar S. FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol Cell Biochem. 2010; 337: 201-212.
44. Oi N, Yuan J, Malakhova M, et al. Resveratrol induces apoptosis by directly targeting Ras-GTPase-activating protein SH3 domain-binding protein 1. Oncogene. 2014.
45. Zhang P, Li H, Yang B, et al. Biological significance and therapeutic implication of resveratrol-inhibited Wnt, Notch and STAT3 signaling in cervical cancer cells. Genes Cancer. 2014; 5: 154-164.
46. Jiang H, Zhang L, Kuo J, et al. Resveratrol-induced apoptotic death in human U251 glioma cells. Mol Cancer Ther. 2005; 4: 554-561.
47. Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004; 3: 71-84.
48. Liu B, Zhou Z, Zhou W, et al. Resveratrol inhibits proliferation in human colorectal carcinoma cells by inducing G1/Sphase cell cycle arrest and apoptosis through caspase/cyclinCDK pathways. Mol Med Rep. 2014; 10: 1697-1702.
49. Estrov Z, Shishodia S, Faderl S, et al. Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 2003; 102: 987-995.
50. Bishayee A, Barnes KF, Bhatia D, et al. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev Res (Phila). 2010; 3: 753-763.
51. Lin MT, Yen ML, Lin CY, Kuo ML. Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol. 2003; 64: 1029-1036.
52. Yu H, Pan C, Zhao S, et al. Resveratrol inhibits tumor necrosis factor-alpha-mediated matrix metalloproteinase-9 expression and invasion of human hepatocellular carcinoma cells. Biomed Pharmacother. 2008; 62: 366-372.
53. Fu Y, Chang H, Peng X, et al. Resveratrol inhibits breast cancer stemlike cells and induces autophagy via suppressing Wnt/beta-catenin signaling pathway. PLoS One. 2014; 9: E102535.
54. Vislovukh A, Kratassiouk G, Porto E, et al. Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744. Br J Cancer. 2013; 108: 2304-2311.
55. Han Z, Yang Q, Liu B, et al. MicroRNA-622 functions as a tumor suppressor by targeting K-Ras and enhancing the anticarcinogenic effect of resveratrol. Carcinogenesis. 2012; 33: 131-139.
56. Dhar S, Hicks C, Levenson AS. Resveratrol and prostate cancer: Promising role for microRNAs. Mol Nutr Food Res. 2011; 55: 1219-1229.
57. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, et al. Resveratrol and clinical trials: The crossroad from in vitro studies to human evidence. Curr Pharm Des. 2013; 19: 6064-6093.
58. Smoliga JM, Blanchard O. Enhancing the Delivery of Resveratrol in Humans: If Low Bioavailability is the Problem, What is the Solution? Molecules. 2014; 19: 17154-17172.
59. Stevens JF, Taylor AW, Deinzer ML. Quantitative analysis of xanthohumol and related prenylflavonoids in hops and beer by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 1999; 832: 97-107.
60. Wang Q, Ding ZH, Liu JK, Zheng YT. Xanthohumol, a novel anti-HIV-1 agent purified from Hops Humulus lupulus. Antiviral Res. 2004; 64: 189-194.
61. Gerhäuser C. Broad spectrum anti-infective potential of xanthohumol from hop (Humulus lupulus L.) in comparison with activities of other hop constituents and xanthohumol metabolites. Mol Nutr Food Res. 2005; 49: 827-831.
62. Suh KS, Rhee SY, Kim YS, et al. Xanthohumol modulates the expression of osteoclast-specific genes during osteoclastogenesis in RAW264.7 cells. Food Chem Toxicol. 2013; 62: 99-106.
63. Nozawa H. Xanthohumol, the chalcone from beer hops (Humulus lupulus L.), is the ligand for farnesoid X receptor and ameliorates lipid and glucose metabolism in KK-A(y) mice. Biochem Biophys Res Commun. 2005; 336: 754-761.
64. Liu Y, Gao X, Deeb D, et al. Anticancer agent xanthohumol inhibits IL-2 induced signaling pathways involved in T cell proliferation. J Exp Ther Oncol. 2012; 10: 1-8.
65. Milligan SR, Kalita JC, Pocock V, et al. The endocrine activities of 8-prenylnaringenin and related hop (Humulus lupulus L.) flavonoids. J Clin Endocrinol Metab. 2000; 85: 4912-4915.
66. Monteiro R, Faria A, Azevedo I, Calhau C. Modulation of breast cancer cell survival by aromatase inhibiting hop (Humulus lupulus L.) flavonoids. J Steroid Biochem Mol Biol. 2007; 105: 124-130.
67. Gerhauser C, Alt A, Heiss E, et al. Cancer chemopreventive activity of Xanthohumol, a natural product derived from hop. Mol Cancer Ther. 2002; 1: 959-969.
68. Drenzek JG, Seiler NL, Jaskula-Sztul R, et al. Xanthohumol decreases Notch1 expression and cell growth by cell cycle arrest and induction of apoptosis in epithelial ovarian cancer cell lines. Gynecol Oncol. 2011; 122: 396-401.
69. Pan L, Becker H, Gerhäuser C. Xanthohumol induces apoptosis in cultured 40-16 human colon cancer cells by activation of the death receptorand mitochondrial pathway. Mol Nutr Food Res. 2005; 49: 837-843.
70. Henderson MC, Miranda CL, Stevens JF, et al. In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops, Humulus lupulus. Xenobiotica. 2000; 30: 235-251.
71. Lust S, Vanhoecke B, Janssens A, et al. Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. Mol Nutr Food Res. 2005; 49: 844-850.
72. Monteghirfo S, Tosetti F, Ambrosini C, et al. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. Mol Cancer Ther. 2008; 7: 2692-2702.
73. Dell'Eva R, Ambrosini C, Vannini N, et al. AKT/NF-kappaB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer. 2007; 110: 2007-2011.
74. Zhao F, Nozawa H, Daikonnya A, et al. Inhibitors of nitric oxide production from hops (Humulus lupulus L.). Biol Pharm Bull. 2003; 26: 61-65.
75. Kim SY, Lee IS, Moon A. 2-Hydroxychalcone and xanthohumol inhibit invasion of triple negative breast cancer cells. Chem Biol Interact. 2013; 203: 565-572.
76. Tan KW, Cooney J, Jensen D, et al. Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Mol Nutr Food Res. 2014.
77. van Breemen RB, Yuan Y, Banuvar S, et al. Pharmacokinetics of prenylated hop phenols in women following oral administration of a standardized extract of hops. Mol Nutr Food Res. 2014; 58: 1962-1969.
78. De Araujo QR, Gattward JN, Almoosawi S, et al. Cacao and Human Health: From Head to Foot -A Review. Crit Rev Food Sci Nutr. 2013 Aug 24. [Epub ahead of print].
79. Ramiro-Puig E, Castell M. Cocoa: Antioxidant and immunomodulator. Br J Nutr. 2009; 101: 931-940.
80. Sánchez-Rabaneda F, Jáuregui O, Casals I, et al. Liquid chromatographic/electrospray ionization tandem mass spectrometric study of the phenolic composition of cocoa (Theobroma cacao). J Mass Spectrom. 2003; 38: 35-42.
81. Rodríguez-Ramiro I, Ramos S, López-Oliva E, et al. Cocoa-rich diet prevents azoxymethane-induced colonic preneoplastic lesions in rats by restraining oxidative stress and cell proliferation and inducing apoptosis. Mol Nutr Food Res. 2011; 55: 1895-1899.
82. Oleaga C, García M, Solé A, et al. CYP1A1 is overexpressed upon incubation of breast cancer cells with a polyphenolic cocoa extract. Eur J Nutr. 2012; 51: 465-476.
83. Romier-Crouzet B, Van De Walle J, During A, et al. Inhibition of inflammatory mediators by polyphenolic plant extracts in human intestinal Caco-2 cells. Food Chem Toxicol. 2009; 47: 1221-1230.
84. Carnésecchi S, Schneider Y, Lazarus SA, et al. Flavanols and procyanidins of cocoa and chocolate inhibit growth and polyamine biosynthesis of human colonic cancer cells. Cancer Lett. 2002; 175: 147-155.
85. Siddique HR, Liao DJ, Mishra SK, et al. Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. Int J Cancer. 2012; 131: 1720-1731.
86. Mackenzie GG, Adamo AM, Decker NP, Oteiza PI. Dimeric procyanidin B2 inhibits constitutively active NF-kappaB in Hodgkin's lymphoma cells independently of the presence of IkappaB mutations. Biochem Pharmacol. 2008; 75: 1461-1471.
87. Kenny TP, Keen CL, Jones P, Kung HJ, et al. Cocoa procyanidins inhibit proliferation and angiogenic signals in human dermal microvascular endothelial cells following stimulation by low-level H2O2. Exp Biol Med (Maywood). 2004; 229: 765-771.
88. Okano J, Nagahara T, Matsumoto K, Murawaki Y. Caffeine inhibits the proliferation of liver cancer cells and activates the MEK/ERK/EGFR signalling pathway. Basic Clin Pharmacol Toxicol. 2008; 102: 543-551.
89. Qi W, Qiao D, Martinez JD. Caffeine induces TP53-independent G(1)-phase arrest and apoptosis in human lung tumor cells in a dose-dependent manner. Radiat Res. 2002; 157: 166-174.
90. Dai Y, Yu C, Singh V, et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 2001; 61: 5106-5115.
91. Bode AM, Dong Z. The enigmatic effects of caffeine in cell cycle and cancer. Cancer Lett. 2007; 247: 26-39.
92. Hashimoto T, He Z, Ma WY, et al. Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res. 2004; 64: 3344-3349.
93. Foukas LC, Daniele N, Ktori C, et al. Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases. Differential effects on lipid kinase and protein kinase activities. J Biol Chem. 2002; 277: 37124-37130.
94. Efferth T, Fabry U, Glatte P, Osieka R. Expression of apoptosis-related oncoproteins and modulation of apoptosis by caffeine in human leukemic cells. J Cancer Res Clin Oncol. 1995; 121: 648-656.
95. Krajka-Kuzniak V, Paluszczak J, Szaefer H, Baer-Dubowska W. Betanin, a beetroot component, induces nuclear factor erythroid-2-related factor 2-mediated expression of detoxifying/antioxidant enzymes in human liver cell lines. Br J Nutr. 2013; 110: 2138-2149.
96. Szaefer H, Krajka-Kuzniak V, Ignatowicz E, et al. Evaluation of the effect of beetroot juice on DMBA-induced damage in liver and mammary gland of female Sprague-Dawley rats. Phytother Res. 2014; 28: 55-61.
97. Zielinska-Przyjemska M, Olejnik A, Kostrzewa A, Luczak M, et al. The beetroot component betanin modulates ROS production, DNA damage and apoptosis in human polymorphonuclear neutrophils. Phytother Res. 2012; 26: 845-852.
98. Licznerska BE, Szaefer H, Murias M, et al. Modulation of CYP19 expression by cabbage juices and their active components: Indole-3-carbinol and 3, 3'-diindolylmethene in human breast epithelial cell lines. Eur J Nutr. 2013; 52: 1483-1492.
99. Szaefer H, Licznerska B, Krajka-Kuzniak V, et al. Modulation of CYP1A1, CYP1A2 and CYP1B1 expression by cabbage juices and indoles in human breast cell lines. Nutr Cancer. 2012; 64: 879-888.
100. Smiechowska A, Bartoszek A, Namiesnik J. [Cancer chemopreventive agents: Glucosinolates and their decomposition products in white cabbage (Brassica oleracea var. capitata)]. Postepy Hig Med Dosw (Online). 2008; 62: 125-140. Polish.